Internal medicine

Adverse effect

Dosing

Oncology

Malignant pleural effusion

Lung cancer

ALK inhibitor

Crizotinib

Response Evaluation Criteria in Solid Tumors

Phases of clinical research

Clinical trial

Medicine

The Lancet Respiratory Medicine

Ensartinib has activity and is well tolerated in patients with crizotinib-refractory, ALK-positive NSCLC, including those with brain metastases. The role of ensartinib in patients in whom other second-generation ALK inhibitors have been unsuccessful warrants further studies.

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial